PriceSensitive

This cannabis brand is growing across popular categories

Cannabis, Market News
TSXV:LFST
18 May 2023 11:01 (EDT)

Source: Cannmart.com

Lifeist’s (TSXV:LFST) subsidiary, CannMart Inc. reported strong sales growth and product breadth expansion.

The Toronto-based health-tech company’s partner brands Zest Cannabis and Rilaxe continue to experience sales growth and product expansion in important markets and categories.

Zest has achieved average store penetration of 20 per cent across Canada, with Rilaxe achieving 30 per cent market penetration in Manitoba and Saskatchewan, with new SKUs expected to launch in Ontario and Québec by the end of the year.

Highlights:

Rilaxe has also experienced success across Canada, and plans to expand its product range by Q4 2023, including:

CannMart’s CEO, Daniel Stern said that these two brands are playing an important role driving sales for and have become valuable additions to Lifeist’s growing portfolio.

“Zest and Rilaxe are complimentary to CannMart’s best-selling concentrate brand, Roilty, with Zest offering premium quality extract-infused pre-roll and Liquid Diamond vape products, and Rilaxe with health-conscious dried fruit edibles and soon canna-cigar Rilaxe Berri Blunts. I look forward to continue to work with these brands to grow market share and expand beyond traditional product categories.”

Lifeist’s CEO, Meni Morim added that Zest and Rilaxe meeti internal targets and driving growth within their respective market categories for CannMart’s brand portfolio.

“These two leading brands are well known and cater to cannabis connoisseurs and health-conscious enthusiast alike. We look forward to the continued market growth and product expansion within the cannabis business unit.”

Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Its portfolio business units include CannMart, CannMart Labs, Australian Vapes, and Mikra.

Lifeist Wellness Inc. (LFST)  opened trading at $0.04 per share.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

Related News